Matthew Adam Gline, an officer and director of Roivant Sciences Ltd., filed an amended Form 144/A on November 10, 2026, providing notice of a proposed sale of 164,136 common shares under Rule 144 of the Securities Act of 1933.

Key Highlights

  • Seller: Matthew Adam Gline, listed as both an officer and director of Roivant Sciences Ltd.
  • Shares proposed for sale: 164,136 common shares, with an aggregate market value of $6,729,576.00, according to the filing.
  • Source of shares: The filing states the shares were acquired on November 10, 2026, through Performance Stock Units granted by the issuer, with payment described as "Services Rendered."
  • Approximate sale date: November 10, 2026, to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services.
  • Shares outstanding: The filing reports 724,561,460 common shares outstanding.
  • Nature of sale: According to the filing's remarks, "The Shares covered by this Form 144 are being sold automatically pursuant to a mandatory, non-discretionary, sell-to-cover arrangement adopted by the Issuer for the purpose of satisfying tax withholding obligations incurred upon the vesting and settlement of equity awards."
  • Prior sales: The filing reports nothing to disclose under securities sold during the past three months.

Mandatory Tax Withholding Sale Following PSU Vesting at Roivant Sciences

According to the amended Form 144/A filing, Matthew Adam Gline notified the SEC of a proposed sale of 164,136 Roivant Sciences Ltd. common shares, listed on NASDAQ:ROIV. The filing identifies Gline as both an officer and director of the company. The shares carry an aggregate market value of $6,729,576.00 as reported in the notice, and the proposed broker for the transaction is Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004.

The filing states the shares were acquired on November 10, 2026, through Performance Stock Units issued by the company, with the nature of payment recorded as "Services Rendered." The filing was submitted as an amendment to a prior submission with accession number 0001950047-26-010941. The amendment added remarks clarifying that the sale is part of a "mandatory, non-discretionary, sell-to-cover arrangement adopted by the Issuer" to cover tax withholding obligations arising from the vesting and settlement of equity awards, rather than a discretionary market sale by the reporting person.

The company's registered address is listed as 50 Broadway, London, United Kingdom, SW1H 0DB. The filing indicates 724,561,460 total common shares outstanding at the time of the notice. No prior sales by Gline in the preceding three months were reported.

What Was Disclosed

Roivant Sciences officer and director Matthew Adam Gline filed an amended Form 144/A on November 10, 2026, disclosing a proposed sale of 164,136 common shares valued at $6,729,576.00, acquired via Performance Stock Units and designated for a mandatory sell-to-cover tax withholding arrangement.